Insulin degludec biosimilar（Wanbang Pharma）

德谷胰岛素生物类似药(万邦生化)

Report date: 2025/11/06 20:00:17

Base Information

Drug NameInsulin degludec biosimilar（Wanbang Pharma）
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A